WAM
SLNO

Warberg Asset Management’s Soleno Therapeutics SLNO Stock Holding History

Warberg Asset Management’s Portfolio SLNO Stock Details SLNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-9,000
Closed -$608K – 209
2025
Q3 		$608K Buy
+9,000
New +$667K 0.1% 78

Other funds holding SLNO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Warberg Asset Management's SLNO Position: Q3 2022 in Review

Warberg Asset Management sold out of Soleno Therapeutics (SLNO) in Q3 2022, closing a stake of 6,000 shares — an estimated $16K sold.

Warberg Asset Management first reported a position in SLNO in Q1 2021 and held it in 5 quarters. The position peaked at $38K in Q1 2021. 22 funds tracked by Wall St. Rank hold SLNO as of Q3 2022.

  • Warberg Asset Management reported no remaining Soleno Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Warberg Asset Management sold 6,000 Soleno Therapeutics shares in Q3 2022, an estimated $16K.
  • Warberg Asset Management first reported a position in Soleno Therapeutics in Q1 2021 and held it in 5 quarters.
  • Warberg Asset Management's Soleno Therapeutics position peaked at $38K in Q1 2021.
  • 22 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q3 2022.

Based on Warberg Asset Management's 13F filing for Q3 2022, filed 7 Nov 2022.